Autolus Therapeutics shareholders approve all nine resolutions at 2024 AGM

Autolus Therapeutics plc

Adoption of 2023 annual accounts passed with 190.78M votes for, 35.8K against.
Directors' remuneration report approved: 167.10M for, 23.69M against.
Ernst & Young LLP reappointed as auditors for the coming year.
All four director re-elections passed: Bain (99.52%), Butitta (98.36%), Itin (99.83%), Young (99.12%).
Board authorized to allot shares up to $8,400 nominal value (Resolution 8) and disapply pre-emption rights (Resolution 9).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.